title Flowchart of the editorial process accessdate 2010 06 29 publisher The MedicalLetter, Inc. format pdf ref See also List of medical journals References Reflist External links Official website http www.medicalletter.org DEFAULTSORT MedicalLetter on Drugs and Therapeutics Category Publications ...Infobox journal cover Commented out because image was deleted image tml on drugs w website.gif 200px center discipline Publication language English, French, Italian, Japanese, Spanish abbreviation Med. Lett. Drugs Ther. publisher The MedicalLetter, Inc. country United States history 1959 present frequency Biweekly website http www.medicalletter.org ISSN 1523 2859 The MedicalLetter on Drugs and Therapeutics commonly referred to as The MedicalLetter is a scientific journal providing evaluations of drug s. It has a print and electronic circulation of well over 450,000 subscribers in 125 countries worldwide. Citation needed date April 2011 It is published biweekly 26 issues year in several languages English US and Canadian editions , French Canadian and European editions , Italian, Japanese, and Spanish. The MedicalLetter is published by The MedicalLetter, Inc. , which also publishes the monthly Treatment Guidelines from The MedicalLetter . Editorial process Articles for The MedicalLetter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trial s. A preliminary draft is circulated to every member of the advisory board and 10 20 other investigators with relevant clinical or experimental experience with the article s topic. Drafts are also provided to the Food and Drug Administration FDA and Centers for Disease Control and Prevention CDC and to all first authors of articles cited in the text. The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents ... more details
Orphan date August 2011 Refimprove date October 2010 The Washington Manual of MedicalTherapeutics is a medical textbook first published in 1942 by Wayland MacFarlane, a professor at the Washington University School of Medicine and chief of the internal medicine ward. Described as the bible of the medical ward the Washington Manual of MedicalTherapeutics is now in its Thirty Second Edition and currently it is now the best selling medical textbook in the world, with more than 200,000 copies worldwide. It has been translated into numerous languages including Spanish language Spanish , Portuguese language Portuguese , Greek language Greek , Hungarian language Hungarian , Romanian language Romanian , Turkish language Turkish , Korean language Korean , Japanese language Japanese and both simplified and classical Chinese language Chinese . The book s current editors are Hilary E.L. Reno, Daniel H. Cooper, Andrew J. Krainik, and Sam J. Lubner. External links http www.ovid.com site catalog Book 852.jsp?top 2&mid 3&bottom 7&subsection 11 Washington Manual of MedicalTherapeutics Source Lippincott Williams & Wilkins LWW http www.libreriacortinamilano.it schedalibro offertemese.asp?ISBN 978078176517 Washington Manual of MedicalTherapeutics in libreria italiana LWW DEFAULTSORT Washington Manual Of MedicalTherapeutics Category Washington University in St. Louis Category Medical manuals med book stub ... more details
Primary sources date January 2009 The MedicalLetter, Inc. is a nonprofit organization founded in 1958 by Arthur Kallet , the co founder of Consumers Union , and Harold Aaron. Since 1958, The MedicalLetter, Inc. has no affiliation whatsoever with Consumers Union. Its two flagship publications, The MedicalLetter on Drugs and Therapeutics and Treatment Guidelines from The MedicalLetter , are independent of the pharmaceutical industry. The MedicalLetter, Inc. is supported solely by subscriptions and accepts no advertising, grants, or donations and has had a strict policy in place, since 1959, that in order to retain their objectivity, they will not sell reprints to the pharmaceutical industry. External links Official website http www.medicalletter.org DEFAULTSORT MedicalLetter, Inc. Category Non profit organizations based in the United States Category Medical and health organizations based in the United States US org stub ... more details
Infobox journal cover Deleted image removed image TG logo.jpg 200px center discipline Pharmacology abbreviation Treat. Guidel. Med. Lett. publisher The Medical Letter, Inc. country United States history 2001 present website http medicalletter.org ISSN 1541 2792 Treatment Guidelines from The Medical Letter is published monthly 12 issues year by the non profit organization The Medical Letter, Inc. , which also publishes The Medical Letter on Drugs and Therapeutics . The journal provides reviews of drug classes for the treatment of most primary care disorders, such as diabetes and hypertension . A typical issue of Treatment Guidelines contains recommendations for drugs of choice and comparative drug assessments specifically analyzing a drugs effectiveness, safety, and cost. External links http medicalletter.org Treatment Guidelines website http medlet best.securesites.com downloads Editorialchart.pdf flowchart of the editorial process Category Publications established in 2001 Category Pharmacology journals Category Monthly journals Category English language journals ... more details
Image BfArM Geb ude R ckansicht.jpg thumb Headquarters The Federal Institute for Drugs and Medical Devices in German Bundesinstitut f r Arzneimittel und Medizinprodukte BfArM is a medical regulatory body in Germany . It operates under the Federal Ministry of Health Germany Federal Ministry of Health . It is headquartered in Bonn . BfArM announced that it will accept pure electronic filings eCTD or NeeS from mid February 2010 previously a full paper copy was required . Only those documents requiring signature will be required in paper. ref name The eCTD summit blog cite news work The eCTD summit date February 3, 2010 author Kathie Clark url http theectdsummit.com summit ?p 678 title European Agency Roundup ref See also Medical device References references External links http www.bfarm.de EN Home homepage node.html DEFAULTSORT Federal Institute For Drugs And Medical Devices Category National agencies for drug regulation Category Federal authorities in Bonn med org stub de Bundesinstitut f r Arzneimittel und Medizinprodukte ... more details
The Commission of Inquiry into the Non Medical Use of Drugs , often referred to as the Le Dain Commission after its chair Dean Gerald Le Dain , was a Canadian government commission that was begun in 1969 and completed its work in 1972 . The final report recommended that cannabis be removed from the Narcotic Control Act and that the provinces implement controls on possession and cultivation, similar to those governing the use of alcohol . The report also recommended that the federal government conduct further research to monitor and evaluate changes in the extent and patterns of the use of cannabis and other drugs, and to explore possible consequences to health, and personal and social behaviour, resulting from the controlled legal distribution of cannabis. A total of 365 submissions were presented at the hearings and an additional 50 were forwarded to the Commission s office. About 12,000 people attended and participated in these hearings, which included testimony from a number of prominent individuals including John Lennon on 22 December 1969 in Montreal . ref http beatles.ncf.ca lennon inquiry.html The Le Dain Commission of Inquiry into the Non Medical Use of Drugs The Private Hearing of John Lennon , December 22, 1969, in Montreal ref Although the report was widely praised for its thoroughness and thoughtfullness, its conclusions were largely ignored by the federal government. References Reflist External links http www.druglibrary.org schaffer Library studies ledain ldctoc.html The Report of the Canadian Government Commission of Inquiry into the Non Medical Use of Drugs 1972 Le Dain Commission Report Category Cannabis legal reform in Canada Category Canadian commissions and inquiries Category 1972 disestablishments ... more details
Italic title infobox journal title Pharmacology & Therapeutics abbreviation Pharmacol. Ther. discipline Pharmacology frequency Monthly history 1976 present publisher Elsevier editor S.J. Enna ISSN 0163 7258 eISSN 1879 016X CODEN PHTHDT OCLC 04981366 website http www.elsevier.com wps find journaldescription.cws home 525486 description description link1 http sciencedirect.com science journal 01637258 link1 name Online access impact 8.897 impact year 2009 openaccess optional Pharmacology & Therapeutics is a medical journal medical review journal published by Elsevier . It incorporates Pharmacology & Therapeutics. Part A Chemotherapy, Toxicology and Metabolic Inhibitors and Pharmacology & Therapeutics. Part B General and Systematic Pharmacology , both originally published by Oxford University Press . External links Official http www.elsevier.com wps find journaldescription.cws home 525486 description description med journal stub Category Pharmacology journals Category Elsevier academic journals Category Publications established in 1976 Category English language journals Category Monthly journals fr Pharmacology & Therapeutics ... more details
Unreferenced date September 2008 Infobox Company company name Halozyme Therapeutics logo Image Halozyme Therapeutics Logo.gif company type Public company Public nasdaq HALO company slogan foundation 1998 location San Diego, California , United States USA key people Jonathan E. Lim , President & CEO num employees 130 industry Biopharmaceutical products biologic medical product Biologic s revenue profit 3,799,521 United States dollar USD 2007 homepage http www.Halozyme.com www.halozyme.com Halozyme Therapeutics , based in San Diego, California , is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology , oncology , dermatology and drug delivery markets. http www.halozyme.com Category Companies in the NASDAQ Biotechnology Index Category Companies based in San Diego, California ... more details
, the Drugs released the Was Sport Better in the 70 s single, their final single. Shortly after, a war broke out between the Drugs and rival rap metal band 28 Days over the song Metal VS Hip Hop when 28 Days fans threw cigarette butts at the Drugs, slashed the tyres on their van and destroyed their equipment. Ian Baddley then posted a letter to 28 Days lead singer Jay Dunne on the Drugs website ...Infobox musical artist See Wikipedia WikiProject Musicians name The Drugs background group or band alias origin Sydney , New South Wales , Australia genre Alternative rock , punk rock years active 1999 2005, 2008 2009 label Rubber Records , Shock Records website http www.thedrugs.net.au current members Ian Baddley br Harry Snow br Benny Drill br Mark Tracks br David Live br John Citizen live only The Drugs were a five piece Australian alternative rock band from Sydney. Formed by Ian Baddley in 1999, they released their first single, Pop Song , in 2000. Their debut album, Music s in Trouble , was released in 2002. Their second album, The Very Next Of , was released in 2004. They disbanded in 2005, but reunited in 2008 for a national tour before disbanding again in 2009. A documentary about the band ... as revealed in the documentary Masking Agents. History The drugs formed in 1999. Their first single ... some months later. In 2002, the Drugs won an ARIA for the Only Way is Up and recorded two singles ... articles 2003 02 26 1046064105077.html ref Later that year, the Drugs went back into the studio to record their second album. In 2004, the Drugs released the track I Was a Teenage Voter on Rock ... and Prison Love Song by a fictionalised version of the Drugs. In 2008, the Drugs got back together for the Osama Holiday tour. In 2010, the trailer for the Masking Agents movie was uploaded. The Drugs ... Agents 2011 References references External links Official website http www.thedrugs.net.au The Drugs DEFAULTSORT Drugs, The Category Australian rock music groups Category The Drugs Category Musical groups ... more details
Unreferenced date May 2010 ARYx Therapeutics, Inc. nasdaq ARYX is an United States American bio pharmaceutical company, headquartered in Fremont, California , focused on developing a portfolio of internally discovered product candidates. The company uses its RetroMetabolic Drug Design technology to design molecules that retain the efficacy of original and well established drugs but which are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these original compounds. References Reflist External links http www.aryx.com Official website Pharmaceutical companies of the United States DEFAULTSORT Aryx Therapeutics, Inc. Category Pharmaceutical companies of the United States ... more details
Orphan date February 2009 Unreferenced date February 2007 Pharmacy and Therapeutics is a committee at a hospital or an insurance plan that meets to decide which drugs will appear on that entity s drug formulary. The committee usually consists of both physicians and pharmacists. They must weigh the costs and benefits of each drug and decide which ones provide the most efficacy per dollar. Most generic drugs are available on formularies, except in cases where that class of drugs are no longer considered safe and efficacious. For instance most formularies will not cover barbiturates since their therapeutic index is low compared to benzodiazepines . Barbiturates have a danger of overdosing that occurs at a smaller milligram range than the benzodiazepines. Category Hospitals Pharma stub ... more details
www.acorda.com Acorda.com footnotes intl Acorda Therapeutics nasdaq ACOR , FWB CDG is a biotechnology company based in Hawthorne, New York . Acorda Therapeutics develops drugs to improve therapies that improve ...Use mdy dates date September 2010 Infobox company name Acorda Therapeutics Inc. logo Image Acorda therapeutics inc logo.PNG 220px Acorda Therapeutics caption type Public company Public traded as nasdaq ACOR FWB CDG genre fate predecessor successor foundation Start date 1995 ref name Acorda FAQ http phx.corporate ir.net phoenix.zhtml?c 194451&p irol faq Acorda FAQ ref founder Ron Cohen defunct location city Hawthorne, New York location country United States location locations area served key people Ron Cohen br Andrew R. Blight industry Health care br Biotechnology products Tizanidine Zanaflex br 4 Aminopyridine Ampyra production services revenue profit United States Dollar US 54.7 Million small FY 2009 small ref name 09IncomeStatement wikinvest stock Acorda Therapeutics ACOR Data Income Statement Acorda Therapeutics ACOR annual SEC income statement filing via Wikinvest ref operating income loss United States Dollar US 79.5 Million small FY 2009 small ref name 09IncomeStatement net income loss United States Dollar US 83.9 Million small FY 2009 small ref name 09IncomeStatement assets increase United States dollar US 319 Million small FY 2009 small ref name 09BalanceSheet wikinvest stock Acorda Therapeutics ACOR Data Balance Sheet Acorda Therapeutics ACOR annual SEC balance sheet filing ... Acorda manufactures and markets the drugs Tizanidine Zanaflex and 4 Aminopyridine Ampyra in the United ... of the board of directors of Acorda Therapeutics are ref http phx.corporate ir.net phoenix.zhtml ... Official website http www.acorda.com http topics.nytimes.com top news business companies acorda therapeutics inc index.html Acorda Therapeutics Inc. The New York Times http www.hoovers.com global cobrands nasdaq factsheet.xhtml?ID 121830 Acorda Therapeutics Inc. Hoover s Pharmaceutical companies of the United ... more details
Infobox company company name Osseon Therapeutics, Inc. company logo File Osseon logo.jpg location Santa Rosa, California, USA key people John Stalcup , CEO industry Medical technology products Medical devices homepage http www.osseon.com osseon.com Osseon Therapeutics, Inc. , designs medical devices to treat degenerative bone and joint disease. Based in Santa Rosa, California , the company develops and manufactures devices to treat compression fractures of the thoracic and lumbar vertebral spine. References Reflist http www.beckersorthopedicandspine.com orthopedic spine device implant news item 1544 42 Orthopedic and Spine Device Companies to Know http www.pressdemocrat.com article 20100408 ARTICLES 100409536 1052 OBITS?p all Foreign Sales Boost Santa Rosa Medical Device Maker http www.pressdemocrat.com article 20101014 BUSINESS 101019732 Osseon Signs Deal with Johnson & Johnson http www.mddionline.com article 50 companies watch 0 50 Companies to Watch http www.breitbart.com article.php?id xprnw.20100506.NE99998 DFine, DePuy, and Osseon Making Headway in the US Vertebral Compression Fracture Treatment Market External Links http www.emedicinehealth.com vertebral compression fracture article em.htm Vertebral Compression Fracture information on eMedicineHealth http www.webmd.com osteoporosis vertebral compression fracture California Corporations Category Medical Equipment Manufacturers Category Surgical Instruments Category Interventional Radiology Category Medical Device Manufacturers Category Health care companies of the United States ... more details
Infobox Company name TauRx Therapeutics logo type Public company Public genre foundation Singapore 2002 founder Professor Claude Wischik br Dr K. M. Seng location city location country location Singapore locations area served key people Professor Claude Wischik, small Executive Chairman small br Dr Shay Way Seng, small Managing Director small br John Harry, small Lead Pharmaceutical Strategist small industry Medication Pharmaceuticals products services market cap revenue operating income net income assets equity owner num employees parent divisions subsid homepage http www.taurx.com TauRx Therapeutics footnotes intl yes TauRx Therapeutics Ltd is a startup pharmaceutical company that is based in Singapore . ref cite web last Marchione first Marilynn title Experimental Alzheimer s drug shows early promise publisher Associated Press date 2008 07 30 url http ap.google.com article ALeqM5jK3o2IH 4QHTz4i5e9OlzzFCA2pgD927P6QO0 accessdate 2008 07 31 ref The company was founded in 2002 by the late gynecologist , surgeon and venture capitalist K. M. Seng and the research biologist Claude Wischik who is currently its CEO. In 1988 Wischik and coworkers discovered that abnormal fibres of tau protein form inside nerve cells in patients with Alzheimer disease , and that their aggregation correlatates to the development of dementia . The company has focused on the development of drugs that dissolve tau fibres in an attempt to manage patients with Alzheimer. Rember is an investigational drug for this purpose by TauRx Therapeutics. ref cite web last Wilkinson first Emma title Alzheimer s drug halts decline publisher BBC date 2006 07 29 url http news.bbc.co.uk 2 hi health 7525115.stm BBC news accessdate 2008 07 29 ref References references External links http www.taurx.com Official site Category Pharmaceutical companies Category Companies of Singapore ... more details
infobox company name Opsona Therapeutics logo Image Opsona Therapeutics logo 200x73.jpg 200px Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune Inflammation inflammatory conditions, cancer s and infectious disease s. ref http www.irishtimes.com newspaper innovation 2009 0302 1224241917142.html Article in the Irish Times ref ref http www.sbpost.ie post pages p story.aspx qqqt People In Business qqqm nav qqqid 39708 qqqx 1.asp Sunday Business Post article ref ref http investing.businessweek.com research stocks private snapshot.asp?privcapId 20741516 BusinessWeek company profile ref Based in Ireland , Opsona is a spin out from Trinity College Dublin TCD ref http www.irishtimes.com newspaper finance 2008 0623 1214047001272.html Article in the Irish Times ref . Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field ref http www.topuniversities.com worlduniversityrankings results 2007 overall rankings top 100 universities Times Higher Educational Supplement QS World University Rankings 2007 ref . Opsona s research is primarily focused on the role of Toll like receptors TLRs and TLR signalling in human innate immunity . The company was founded in 2004 by three immunologists Professor Luke O Neill ref http www.irishexaminer.ie ireland trinity team makes vaccine discovery 90894.html Article in the Irish Examiner ref Professor Kingston Mills ref http www.tcd.ie Biochemistry research k mills.php Article on the Trinity College Dublin website ref Professor Dermot Kelleher ref http www.tcd.ie Communications news news.php?headerID 1108&vs date 2009 2 1 Article on the Trinity College Dublin website ref Opsona s main investors are international and life science focused Inventages Venture Capital Bahamas ref http www.fiercebiotech.com press releases opsona therapeutics closes eur18m funding 0 Article on Fierce Biotech ref Seroba Bioventures ... more details
coord 40.550722 74.4230711 type landmark region US NJ display title PTC Therapeutics is a pharmaceutical company. It is headquartered in South Plainfield , New Jersey . They are the company responsible for the development of PTC124 . ref name pmid17096300 cite journal author Hamed SA title Drug evaluation PTC 124 a potential treatment of cystic fibrosis and Duchenne muscular dystrophy journal IDrugs the investigational drugs journal volume 9 issue 11 pages 783 9 year 2006 pmid 17096300 doi ref As of September 2009, PTC has entered into an agreement with Hoffmann La Roche Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC s GEMS technology for the identification of small molecules will enable Roche to address important disease mechanisms that were intractable with conventional approaches. ref http www.firstwordplus.com Fws.do?articleid A2B13ACB78294EB0A27EE127D8339BF3 ref References references Further reading ref name Schneider2009 Cite journal title Firm Aims to Regulate RNA in Rare Diseases url http www.genengnews.com articles chitem.aspx?aid 2869 year 2009 author Schneider, Ilene journal Genetic Engineering & Biotechnology News pages 14 volume 29 issue 8 accessdate 2009 04 25 postscript None ref External links http www.ptcbio.com DEFAULTSORT PTC Therapeutics Category Biotechnology Category Clinical research Category Pharmaceutical industry Category Pharmacology Category Pharmacy Category Companies based in New Jersey pharmacology stub ... more details
Insert Therapeutics , Inc., now Calando Pharmaceuticals, Inc., is a medical research company that uses nanobiotechnology specializing in therapeutic agents that are conjugation chemistry conjugate d, to facilitate and enhance drug delivery . The small company was founded in 2000, is located in Pasadena, California , and majority owned by Arrowhead Research Corporation . The conjugates consist of a cyclodextrin containing polymer Cyclosert that acts as a drug delivery system, and a linked medication, such as a chemotherapeutic drug of already proven efficacy. ref name IT 101 http clinicaltrials.gov ct show NCT00333502?order 1 IT 101 trial ref The size of the polymer is designed to fit the specific target, as vessels in a neoplasm allow for leakage of different size of polymers, as in healthy tissue. The leaked conjugates are concentrated in the target area. As a result chemotherapeutic activity is locally enhanced, while general side effects are decreased. ref name IT 101 At least one of their conjugates, IT 101 , has been investigated in a clinical trial at City of Hope National Medical Center . ref name IT 101 References references External links http www.calandopharma.com Calando Pharmaceuticals, Inc. was Insert Therapeutics, Inc. http www.ceruleanrx.com Cerulean Pharma, Inc. IT 101 licensee Category Biotechnology ar ... more details
Repros Therapeutics Inc. NASDAQ RPRX , is a United States US based development stage biopharmaceutical company headquartered in The Woodlands, Texas . Founded in 1987 as Zonagen, it is focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski ref name Joseph S. Podolski Profile http people.forbes.com profile joseph s podolski 67949 Joseph S. Podolski Profile , Forbes.com ref is the CEO of this company. History The company was organized on August 28, 1987 as Zonagen, to try to develop birth control methods based on modification of the zona pellucida a part of the oocyte . The company bought the rights to the research of Bonnie Dunbar, researcher and professor at the Baylor College of Medicine , and attempted to create a contraceptive vaccine. Zonagen, Inc. was formed in 1987 by Dunbar, Baylor and a group of investors that included Ross Perot and Lloyd Bentsen III, son of a former treasury secretary. The company hoped to market Dunbar s invention as a nonsurgical method of sterilizing dogs and cats. In the meantime, Zonagen would help Dunbar continue the pursuit of her life s work the world s first contraceptive vaccine for humans. Her research, which had been progressing well, ground to a complete halt according to Brian Wallstin of the Houston Press newspaper in his article Biological Disaster. ref Brian Wallstin, http www.houstonpress.com 1998 08 20 news biological disaster Biological Disaster , Houston Press Aug 20 1998 ref The company, went public in 1993 with claims that a contraceptive vaccine was imminent. Bonnie Dunbar ended relations with the company and sued them. Zonagen would not develop any commercial product from research relating to the zona pellucida despite naming itself after it. Its next project was to create an adjuvant. These products modify the effects of the active ingredient ... its name to Repros Therapeutics, started to develop other pharmaceutical products for the reproductive ... more details
Infobox company company name Regulus Therapeutics Inc. company logo Deleted image removed Image RegulusTherapeuticsInc.gif 210px company type Private company foundation September 2007 by Alnylam Pharmaceuticals NASDAQ ALNY and Isis Pharmaceuticals NASDAQ ISIS location San Diego, California , USA key people Kleanthis G. Xanthopoulos, Ph.D. President and CEO br Garry E. Menzel, Ph.D. COO and EVP Finance br Neil W. Gibson, Ph.D. CSO br Hubert C. Chen, M.D. VP of Translational Medicine br Lars Karlsson, M.D., Ph.D. VP of Immunology and Fibrosis industry Biotechnology products microRNA therapeutics num employees 54 homepage http www.regulusrx.com www.regulusrx.com Regulus Therapeutics Inc. or Regulus is a biopharmaceutical company focused on the development of microRNA based drugs targeting fibrosis, metabolism and cardiovascular diseases, cancer, HCV and immune related diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. ref name drugdiscoverynews cite web url http www.drugdiscoverynews.com index.php?newsarticle 5030 title Omics & Systems ..., Mike date October 2010 ref ref cite web url http www.genengnews.com gen articles mirna drugs close in on clinical debut 3600 title miRNA Drugs Close In on Clinical Debut publisher Genetic Engineering & Biotechnology News author Liszewski, Kathy date May 15, 2011 ref anti miR Therapeutics Anti miR therapeutics inhibit specific microRNA targets. Animal models showed that modulating microRNAs ... pharmtech Drug Delivery Perspectives in MicroRNA Therapeutics ArticleStandard Article detail 718858 title Perpectives in MictoRNA Therapeutics, publisher Pharmaceutical Technology author Steffy, Kevin ... and commercialization of novel microRNA targeted therapeutics to treat inflammatory diseases such as rheumatoid ... and commercialize microRNA therapeutics targeting microRNA 122 miR 122 for the treatment of hepatitis ... Therapeutics official website cite journal pages 2921 31 doi 10.1172 JCI57275 title Antagonism ... more details
Infobox Company company name IL Therapeutics Inc. company type foundation location 105E 111 Research Drive, Saskatoon, Saskatchewan Saskatoon , Saskatchewan SK , Canada key people industry Biotechnology num employees products homepage IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP Western Life Sciences and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation Pacgen ref name pac Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor pdfs news release20060412.pdf accessdate Sept 9, 2007 ref History Saskatchewan Research Council operates a bio processing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine Pharmaceuticals Currently IL Therapeutics is working on a drug candidate, IL 8 3 73 K11R G31P PAC G31P for relief of Acute Respiratory Distress Syndrome ARDS ref name pac3 Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor releases 20060412.html accessdate Sept 9, 2007 ref The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund SRC Industry Venture Fund. ref name src Citation last Saskatchewan Research Council 2005 2006 Annual Report first author link last2 first2 author2 link title Sustainable Science Solutions date year url http www.src.sk.ca store account download file.cfm?productID 3483&freeDownloadID 538 accessdate Sept 9, 2007 ref The successful progression of G31PRecently the University of Saskatchewan Industry Liaison Office ILO decided ... Releases U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications date ... more details
Infobox Company company name Prime Therapeutics company logo File Prime therapeutics llc.jpg 250px div style height 0.5em clear both div company type Limited Liability Corporation foundation 1998, created by a merger location Eagan, Minnesota key people Eric Elliott, CEO br Don Amorosi, COO br David Lassen, PharmD, Chief Clinical Officer br Charles Roehrick, CFO br Duane Barnes, SVP Consumer Delivery br Jacqueline Chase, SVP Human Resources br John Mielke, CBO & CTO br Cameron Olig, SVP, Client Services br Sara Ratner, Chief Compliance Office br Peter Wickersham, SVP, Cost of Care br Matt Yordy, SVP, Business Development industry Pharmacy Benefit Management, Mail Order Pharmacy num employees 2,100 2011 parent Blue Cross and Blue Shield of Alabama , Blue Cross and Blue Shield of Florida , Blue Cross and Blue Shield of Illinois , Blue Cross and Blue Shield of Kansas , Blue Cross and Blue Shield ... URL http www.primetherapeutics.com TOC Prime Therapeutics LLC is a Pharmacy Benefit Manager PBM ..., New Mexico, North Carolina, North Dakota, Oklahoma, Texas and Wyoming. Prime Therapeutics operates ..., IL , Jacksonville, Florida , Hoover, Alabama , Pittsburgh, PA and Washington, D.C. Prime Therapeutics ... , Express Scripts Incorporated , and Catalyst Rx. Prime Therapeutics covers nearly 20 million lives ... and medical benefit. History 1987 Pharmacy Gold is established as the pharmacy department ... and service bureau, and is renamed Prime Therapeutics, Inc. Prime is a privately held corporation ... Cross and Blue Shield of Texas purchases equity ownership 2004 Prime Therapeutics, LLC is formed ... Prime Therapeutics ref Cite news title Our Story url http www.primetherapeutics.com our story.html ... Electronic Refill Requests REFREQ REFRES Medication History Requests RXHREQ RXHRES Prime Therapeutics as a PBM also supports the Medical billing United States Electronic Billing Process ANSI X12 ... Pharmacy Benefit Management companies based in the United States Category Medical and health organizations ... more details
Antibe Therapeutics is a Toronto based pharmaceutical research and development company developing inflammation reducing drugs. ref http www.antibe therapeutics.com ref The conceived mechanism of action is to deliver a gaseous mediator , specifically hydrogen sulfide to sites of inflammation or injury within the human body. Hydrogen sulfide enhances the resolution of injury and repair of damage. Antibe was founded by John L. Wallace , co founder of NicOx , the company that was the first to commercialize gaseous mediator technology. Antibe s board of directors includes Louis Ignarro , awarded the 1998 Nobel Prize in Physiology or Medicine for the basic research that underpins gaseous mediator technology, and Dr. Daniel K. Podolsky, Presient of the University of Texas Southwestern . Antibe s products have not yet been approved by the Food and Drug Administration . The lead drug, ATB 346, is a hydrogen sulfide releasing derivative of naproxen, a commonly used non steroidal anti inflammatory drug . Unlike naproxen, ATB 346 does not induce damage in the gastrointestinal tract. Canada company stub References reflist External links http www.nicox.com Official website of NicOx http www.nitricoxideonline.net Nitric Oxide Knowledge Center Website of NicOx Category Pharmaceutical companies of France Category SBF 120 de Nicox fr Nicox http www.ncbi.nlm.nih.gov pmc articles PMC1363746 ... more details
Durata Therapeutics , established in 2009, is a clinical development stage pharmaceutical company. Durata focuses on new therapeutics to treat infectious diseases . Durata has several projects in its pipeline, most notably the antibacterial, dalbavancin . The company acquired this long acting semisynthetic lipoglycopeptide antibiotic from Pfizer in December 2009. ref http www.genengnews.com gen news highlights durata therapeutics acquires pfizer s subsidiary that develops antibiotics 71646582 Durata Therapeutics Acquires Pfizer s Subsidiary that Develops Antibiotics. GEN News Highlights Dec 21, 2009. ref Durata has since initiated two Phase III studies of dalbavancin for intravenous IV treatment of acute bacterial skin and skin structure infections. ref http www.dddmag.com news Durata Begins Dalbavancin Study Enrollment 10511.aspx Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development October 05, 2011. ref References reflist External links http www.duratatherapeutics.com Durata Therapeutics corporate website Portal Companies Pharmaceutical companies of the United States company stub DEFAULTSORT Durata Therapeutics Category Pharmaceutical companies of the United States ... more details
Orphan date January 2012 Infobox Company company name Silence Therapeutics PLC company type Public LSE SLN foundation 1994 industry Pharmaceutical company Pharmaceuticals num employees 50 homepage http www.silence therapeutics.com www.silence therapeutics.com Silence Therapeutics Alternative Investment Market AIM SLN ref cite web title Google Finance Stock Exchange listing for Silence Therapeutics url http www.google.co.uk finance?q LON SLN accessdate 2011 09 16 ref is a biotechnology company that develops Gene therapy gene therapeutic technology based on RNA interference RNAi . They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based in Royal Institution The Royal Institution of Great Britain , Mayfair, London. Profile The targeting, delivery and on going structural modification of sequences are the three platforms for Silence Therapeutics s RNAi therapeutic development. These three platforms are Gene therapy Lipoplexes and polyplexes proprietary delivery using ... and scientific research development of siRNA structural features Silence Therapeutics develops ... Therapeutics AG. More recently in January 2010, Silence Therapeutics merged with Intradigm Corporation ... interference. ref cite web first Stockopedia url http www.stockopedia.co.uk share prices silence therapeutics LON SLN title Stockopedia Silence Therapeutics Company History accessdate 2011 09 16 publisher Stockopedia ref Partnerships Silence Therapeutics has multiple partnerships with other pharmaceutical ... Pharma Dainippon Sumitomo . ref cite web first Silence Therapeutics url http www.silence therapeutics.com content collaborations partnerships.htm title Silence Therapeutics Collaborative Partnerships accessdate 2011 09 26 publisher Silence Therapeutics ref References reflist External links http ... more details
nofootnotes date May 2011 Image Opexa Therapeutics logo.jpg right Opexa Therapeutics corporate logo Opexa Therapeutics nasdaq OPXA , formerly known as PharmaFrontiers , is a biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis , congestive heart failure , and diabetes . The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies. Key products and research include Tovaxin A T cell therapeutic vaccine for multiple sclerosis Heart Cardiac stem cell therapy Diabetes mellitus Diabetes stem cell therapy Location Opexa Therapeutics is located in The Woodlands, Texas The Woodlands , Texas convert 30 mi km north of Houston , Texas . The company has a convert 10200 sqft m2 abbr on facility on convert 3 acre m2 in The Woodlands, Texas The Woodlands . This location provides space for pipeline development through R & D a specialized Flow cytometry and Microscopy lab support of clinical trials with Good manufacturing practice GMP manufacturing Suites Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance as well as administrative support space. External links http www.opexatherapeutics.com Opexa Therapeutics webpage http news.bbc.co.uk 1 hi health 4787430.stm BBC Article 3 8 06 http www.upi.com HealthBusiness view.php?StoryID 20060309 042811 3384r UPI Health Brief Category Companies based in Texas Category Biotechnology companies Category Vaccination related organizations ... more details
Encyclopedia
top
